950858-06-7

Basic information

• Product Name: 2,6-DIFLUORO-4-IODOPHENOL
• Synonyms: 2,6-DIFLUORO-4-IODOPHENOL
• CAS NO: 950858-06-7
• Molecular Formula: C₆H₃F₂IO
• Molecular Weight: 255.99
• Mol File: 950858-06-7.mol
• Article Data: 2

Chemical Properties

• Melting Point: 70-73℃
• Boiling Point: 208.932°C at 760 mmHg
• Flash Point: 80.16°C
• Appearance: /
• Density: 2.163g/cm³
• Vapor Pressure: 0.144mmHg at 25°C
• Refractive Index: 1.61
• Water Solubility: Insoluble in water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: 2,6-DIFLUORO-4-IODOPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIFLUORO-4-IODOPHENOL(950858-06-7)
• EPA Substance Registry System: 2,6-DIFLUORO-4-IODOPHENOL(950858-06-7)

Safety Data

• Hazardous Substances Data: 950858-06-7(Hazardous Substances Data)

Usage

General Description

2,6-Difluoro-4-iodophenol is a chemical compound with the molecular formula C6H3F2IO. It is a derivative of phenol and belongs to the class of halogenated phenols. This chemical is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various compounds. It has potential applications in the development of pharmaceuticals, agrochemicals, and other industrial products. Additionally, 2,6-Difluoro-4-iodophenol is used as a reagent in chemical reactions, particularly in the formation of carbon-carbon and carbon-heteroatom bonds. Its unique structure and properties make it a valuable tool in the field of chemical and pharmaceutical research.

InChI:InChI=1/C6H3F2IO/c7-4-1-3(9)2-5(8)6(4)10/h1-2,10H

Upstream product

• 28177-48-2 2,6-difluorophenol 

Downstream Products

• 886762-68-1 2,6-difluoro-4-iodoanisole 

Relevant articles and documents

A Novel 18F-Labeled Radioligand for Positron Emission Tomography Imaging of 11β-Hydroxysteroid Dehydrogenase (11β-HSD1): Synthesis and Preliminary Evaluation in Nonhuman Primates

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion of cortisone to cortisol and controls a key pathway in the regulation of stress. Studies have implicated 11β-HSD1 in metabolic diseases including type 2 diabetes and obesity, as well as stress-related disorders and neurodegenerative diseases, such as depression and Alzheimer's disease (AD). We have previously developed [11C]AS2471907 as a PET radiotracer to image 11β-HSD1 in the brain of nonhuman primates and humans. However, the radiosynthesis of [11C]AS2471907 was unreliable and low-yielding. Here, we report the development of the 18F-labeled version [18F]AS2471907, including the synthesis of two iodonium ylide precursors and the optimization of 18F-radiosynthesis. Preliminary PET experiments, composed of a baseline scan of [18F]AS2471907 and a blocking scan with the reversible 11β-HSD1 inhibitor ASP3662 (0.3 mg/kg), was also conducted in a rhesus monkey to verify the pharmacokinetics of [18F]AS2471907 and its specific binding in the brain. The iodonium ylide precursors were prepared in a seven-step synthetic route with an optimized overall yield of 7sim;2%. [18F]AS2471907 was synthesized in good radiochemical purity, with the ortho regioisomer of iodonium ylide providing greater radiochemical yield as compared with the para regioisomer. In monkey brain, [18F]AS2471907 displayed high uptake and heterogeneous distribution, while administration of the 11β-HSD1 inhibitor ASP3662 significantly reduced radiotracer uptake, thus demonstrating the binding specificity of [18F]AS2471907. Given the longer half-life of F-18 and feasibility for central production and distribution, [18F]AS2471907 holds great promise to be a valuable PET radiotracer to image 11β-HSD1 in the brain.